Delcath Systems FY2024 EPS Forecast Boosted by HC Wainwright

Delcath Systems, Inc. (NASDAQ:DCTH) – Equities research analysts at HC Wainwright raised their FY2024 earnings per share estimates for shares of Delcath Systems in a research note issued to investors on Monday, November 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.90) for the year, up from their prior estimate of ($1.18). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Delcath Systems’ Q4 2024 earnings at ($0.10) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($0.87) EPS, FY2026 earnings at ($0.23) EPS and FY2027 earnings at $0.76 EPS.

Several other equities analysts have also commented on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a research report on Friday, October 18th. StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Finally, Stephens reaffirmed a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Price Performance

Shares of DCTH stock opened at $9.23 on Thursday. The firm’s 50-day simple moving average is $9.71 and its 200-day simple moving average is $8.43. Delcath Systems has a 1-year low of $2.30 and a 1-year high of $12.88. The firm has a market cap of $295.08 million, a P/E ratio of -6.97 and a beta of 0.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of DCTH. Riverwater Partners LLC acquired a new position in Delcath Systems during the 3rd quarter worth approximately $161,000. Levin Capital Strategies L.P. grew its holdings in Delcath Systems by 12.2% during the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock valued at $262,000 after purchasing an additional 5,969 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Delcath Systems during the 2nd quarter worth $370,000. Renaissance Technologies LLC acquired a new position in Delcath Systems in the 2nd quarter worth $694,000. Finally, Marshall Wace LLP boosted its position in Delcath Systems by 7.0% in the 2nd quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock valued at $776,000 after buying an additional 6,066 shares during the last quarter. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.